RAS inhibitors: potential for cancer therapeutics

Mol Med Today. 2000 Oct;6(10):398-402. doi: 10.1016/s1357-4310(00)01789-5.

Abstract

As RAS oncoproteins play a major role in human malignancy, inhibiting RAS function is a promising approach for developing anticancer therapies. Among these approaches are agents such as farnesyltransferase inhibitors (FTIs) and the nontoxic farnesylcysteine analogue farnesylthiosalicylic acid (FTS) that dislodges all RAS isoforms from the membrane, as well as methods to restore regulation of RAS-GTP levels and to alter the interaction of RAS-GTP with downstream targets.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Alkyl and Aryl Transferases / antagonists & inhibitors*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Drug Design
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Farnesol / analogs & derivatives*
  • Farnesol / pharmacology
  • Farnesyltranstransferase
  • Humans
  • Neoplasms / drug therapy*
  • Salicylates / pharmacology
  • ras Proteins / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Salicylates
  • farnesylthiosalicylic acid
  • Farnesol
  • Alkyl and Aryl Transferases
  • Farnesyltranstransferase
  • ras Proteins